WHO ICTRP trial
Efficacy and safety of intravenous magnesium for the prevention of…
JPRN-jRCTs031210300 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCTs031210300 |
|---|---|
| Public title | Efficacy and safety of intravenous magnesium for the prevention of cisplatin-induced nephrotoxicity in patients with esophageal squamous cell carcinoma who received neoadjuvant chemotherapy: A phase II study. (MAGICIAN study (KDOG 2101)) |
| Scientific title | Efficacy and safety of intravenous magnesium for the prevention of cisplatin-induced nephrotoxicity in patients with esophageal squamous cell carcinoma who received neoadjuvant chemotherapy: A phase II study. (MAGICIAN study (KDOG 2101)) |
| Primary sponsor | Watanabe Akinori |
| Secondary sponsors | Mohri Junichi |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Conditions | esophageal squamous cell carcinoma esophageal squamous cell carcinoma;D000077277;esophageal squamous cell carcinoma |
| Interventions | Magnesium sulfate (8 mEq) will be administered before the administration of cisplatin as a IV infuison.;D008278;magnesium sulfate, cisplatin-induced nephrotoxicity |
| Registration date | Aug 9, 2021 |
| Target size | 30 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: